CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

Journal of the National Cancer Institute

Volumn 97, Issue 1, 2005, Pages 30-39

  Jin, Yan ^a   Desta, Zeruesenay ^a   Stearns, Vered ^d   Ward, Bryan ^a   Ho, Herbert ^a   Lee, Kyung Hoon ^a   Skaar, Todd ^a   Storniolo, Anna Maria ^a   Li, Lang ^a   Araba, Adjei ^c   Blanchard, Rebecca ^e   Nguyen, Anne ^a   Ullmer, Lynda ^b   Hayden, Jill ^b   Lemler, Suzanne ^f   Weinshilboum, Richard M ^c   Rae, James M ^b   Hayes, Daniel F ^b   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; AMIODARONE; CITALOPRAM; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENDOXIFEN; FLUOXETINE; METOCLOPRAMIDE; NORTAMOXIFEN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; TAMOXIFEN; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOT FLUSH; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; WILD TYPE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TAMOXIFEN; TIME FACTORS;

EID: 19944434201     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji005     Document Type: Article

References (35)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Insts 1998;90:1371-88.
3. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-61.
4. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56.
5. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 1984;50:199-205.
6. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999;17:2633-8.
7. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977;75:305-16.
8. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
9. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
10. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2003;791:245-53.
11. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53:171-8.
12. Chen G, Yin S, Maiti S, Shao X. 4-Hydroxytainoxifen sulfation metabolism. J Biochem Mol Toxicol 2002;16:279-85.
13. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75.
14. Fried KM, Wainer IW. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994;655:261-8.
15. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2136 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
16. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000;46:1072-7.
17. Hiratsuka M, Agatsuma. Y, Omori F, Narahara K, Inoue T, Kishikawa Y, et al. High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol Pharm Bull 2000;23:1131-5.
18. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002;58:417-21.
19. Le Corte P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, et al. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004;76:139-53.
20. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997;7:405-9.
21. Coughtrie MW, Gilissen RA, Shek B, Strange RC, Fryer AA, Jones PW, et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 1999;337:45-9.
22. Hollander M, Wolfe D. Nonparametric statistical methods. New York (NY): John Wiley & Sons; 1973.
23. Westfall P, Hochberg Y, Wolfinger RD, Rom D, Tobias RD. Multiple comparisons and mutiple tests. Cary (NC): SAS Institute; 1999.
24. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-43.
25. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
26. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998;7:24-32.
27. Lien EA, Anker G, Ueland PM. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Biol 1995;55:229-31.
28. Yao JC, Thomakos N, McLaughlin P, Buchholz TA, Kudelka AP. Tamoxifen-induced thrombocytopenia. Am J Clin Oncol 1999;22:529-32.
29. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999;9:669-82.
30. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001;70:1-10.
31. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.
32. Stearns V, Beebe KL, lyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.
33. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-9.
34. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5.
35. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.